Potential Benefits of GLP-1 Receptor Agonists in Type 1 Diabetes Management
Pharmaceutical companies originally developed glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter inhibitors to treat type 2 diabetes. Several of…
Pharmaceutical companies originally developed glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter inhibitors to treat type 2 diabetes. Several of…